ARNT deficiency represses pyruvate dehydrogenase kinase 1 to trigger ROS production and melanoma metastasis

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Research

Background:

• Metabolic alterations in melanoma cells are crucial for metastasis but not fully understood.
• Aryl hydrocarbon receptor nuclear translocator (ARNT) plays a role in cellular metabolism and cancer progression.

Purpose of the Study:

• To elucidate the metabolic changes required for melanoma metastasis.
• To investigate the role of ARNT deficiency in melanoma cell metastasis and associated metabolic shifts.

Main Methods:

• Analysis of ARNT, pyruvate dehydrogenase kinase 1 (PDK1), and NAD(P)H quinine oxidoreductase-1 (NQO1) expression in clinical tissue specimens.
• Investigating the effects of ARNT depletion on PDK1, NQO1, and reactive oxygen species (ROS) levels.
• Utilizing N-acetylcysteine (NAC), carbonyl cyanide m-chlorophenyl hydrazone (CCCP), and rotenone to modulate ROS and oxidative phosphorylation.
• Assessing cell migration, invasion, and extravasation in vitro and in mouse models.

Main Results:

• ARNT, PDK1, and NQO1 expression were decreased in melanoma compared to benign nevi.
• ARNT depletion led to decreased PDK1 and NQO1, increasing ROS levels.
• Inhibition of ROS and oxidative phosphorylation, along with NAC treatment, suppressed ARNT/PDK1 deficiency-induced cell migration and invasion.
• ARNT deficiency enhanced glucose uptake, reducing glucose dependence and promoting tumor cell extravasation in vivo.

Conclusions:

• Downregulation of ARNT and PDK1 expression is a prognosticator for melanoma metastasis.
• Metabolic reprogramming, including altered glucose metabolism and oxidative phosphorylation, is essential for metastatic potential in ARNT-deficient melanoma cells.